Survival trends in metastatic bladder cancer in the United States: A population based study

Journal of Cancer Research and Therapeutics

Volumn 11, Issue 1, 2015, Pages 124-128

  Shah, Binay Kumar ^a   Mandal, Rakesh ^b  

^a Landstuhl Regional Medical Center   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

and cisplatin; and End Results; Bladder cancer; doxorubicin; Epidemiology; gemcitabine and cisp++latin; methotrexate; Surveillance; survival; vinblastine

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CAUCASIAN; FEMALE; GENDER; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POPULATION RESEARCH; RACE; SURVIVAL RATE; TREND STUDY; UNITED STATES; CANCER REGISTRY; CANCER STAGING; ETHNIC GROUP; ETHNOLOGY; HEALTH SURVEY; HISTORY; MIDDLE AGED; MORTALITY; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ADULT; AGED; ETHNIC GROUPS; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POPULATION SURVEILLANCE; SEER PROGRAM; SURVIVAL RATE; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84928614014     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.140982     Document Type: Article

References (11)

1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013.
2. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, et al. Bladder Cancer Working Group report. Jpn J Clin Oncol 2010;40 Suppl 1:i57-64.
3. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1988;139:461-9.
5. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003;8:541-52.
6. Surveillance, Epidemiology, and End Results (SEER) Program. SEERFNx01Stat Database: Incidence-SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973-2010 varying)-Linked To County Attributes-Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. Available from: http://www.seer.cancer.gov. [Last accessed 2013 July 16]
7. Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941-8.
8. Hahn-Ast C, Glasmacher A, Mückter S, Schmitz A, Kraemer A, Marklein G, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010;65:761-8.
9. Available from: http://www.seer.cancer.gov/statfacts/html/urinb.html. [Last accessed on 2014 Jul 16].
10. Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid disease and cancer: The need for more relevant conceptual models in health services research. J Clin Oncol 2005;23:7399-404.
11. U.S. Department of Health and Human Services-National Cancer Institute, (NCI). Cancer Incidence - Surveillance, Epidemiology, and End Results (SEER) Registries Research Data; April 2012. Available from: http://www.seer.cancer.gov/data/metadata.html. [Last accessed 2013 July 16]